Shield Therapeutics is a specialty pharmaceutical company focused on the development and commercialisation of late‑stage, hospital‑focused pharmaceuticals which address areas of unmet medical need.
Find out moreOur lead product, Feraccru®, is a novel oral ferric iron therapy that is approved and marketed in the European Union for the treatment of Iron Deficiency (ID) with or without anaemia in adults and in Switzerland for the treatment of Iron Deficiency Anaemia (IDA) in adults with inflammatory bowel disease (IBD).
Find out moreRT @WalbrookPR: PUNT OF THE WEEK: Shield Therapeutics' pill can treat iron deficiency https://t.co/kPTjH6eOgI via @ThisIsMoney
RT @VoxPodcast: Shield Therapeutics - Director/PDMR Shareholding #STX @ShieldTx https://t.co/RxTqeOBc8W #voxmarkets via @voxmarkets
RT @WalbrookPR: Shield Therapeutics (AIM: #STX) @ShieldTx announces that James Karis, Chairman of the Company, has acquired 75,000 Ordinary…
